KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates the addition of selinexor (KPT-330) to RICE chemotherapy in the
treatment of relapsed and refractory aggressive B-Cell Lymphoma, with the goal of improved
response rates (as compared to RICE chemotherapy alone).
Phase:
Phase 1
Details
Lead Sponsor:
Weill Medical College of Cornell University
Collaborators:
FDA Office of Orphan Products Development Karyopharm Therapeutics Inc Karyopharm Therapeutics, Inc The Leukemia and Lymphoma Society